NASDAQ : CYAD

Celyad Oncology S.A.

$0.47 USD

-$0.07 (-12.96%)

Volume
49K
Average Volume
18.58K
Market Capitalization
$14.24M
P/E Ratio
-2.93
Dividend Yield
0.00%
Price Target
Year High
$3.07
Year Low
$0.15
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$3.79
Company Overview

NASDAQ

Georges Rawadi

Biotechnology

Healthcare

CYAD

35

BE

USD

https://www.celyad.com

32 1 039 41 00

151205200

0001637890

Liquidity Metrics

0.17

3.79

3.79

2.39

0.00

Sales & Valuation

$186K

66.92

2.70

-0.77

-0.39

Profitability

-$0.14

-$5.82M

-3131.18%

-3131.18%

-109.67%

-35.77%

P/E Metrics

-2.93

-0.03

-0.03

Analyst Price Target & Rating

N/A

0/5

5 Analysts

%

Poll Results

About Celyad Oncology S.A. (NASDAQ:CYAD) Stock

Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing novel chimeric antigen receptor T (CAR-T) cell therapies aimed at combating various cancers. The company boasts several promising therapeutic candidates in clinical trials. CYAD-101, an allogeneic CAR-T cell therapy, is currently undergoing Phase 1b trials for patients with metastatic colorectal cancer. Another allogeneic, shRNA-based CAR-T candidate, CYAD-211, is in Phase 1 for individuals suffering from relapsed/refractory multiple myeloma. Additionally, CYAD-02, an autologous CAR-T therapy, is being evaluated in Phase 1 for relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, Celyad is developing CYAD-203. This is a non-gene edited al ... logeneic CAR-T candidate engineered to co-express the cytokine interleukin-18 (IL-18) alongside natural killer group 2D ligands (NKG2D), targeting solid tumors. Celyad has also forged strategic alliances. It holds a licensing agreement with Novartis International AG concerning US patents for allogeneic CAR-T cell technology. Furthermore, the company has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to establish a second non-gene-edited allogeneic platform. Founded in 2004, the company was initially named Celyad SA, but rebranded to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.

Frequently Asked Questions

What is the current Celyad Oncology S.A. (CYAD) stock price?

Celyad Oncology S.A.(NASDAQ:CYAD) stock price is $0.47 in the last trading session. During the trading session, CYAD stock reached the peak price of $3.07 while $0.15 was the lowest point it dropped to. The percentage change in CYAD stock occurred in the recent session was --12.96% while the dollar amount for the price change in CYAD stock was -$0.07.

CYAD's industry and sector of operation?

The NASDAQ listed CYAD is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of CYAD?

Georges Rawadi | Chief Executive Officer & Director
Eytan Breman | Director of R&D
Philippe Dechamps | Corporation Sec.
|
|

How many employees does CYAD have?

Number of CYAD employees currently stands at 35. CYAD operates from Axis Business Park, Mont-Saint-Guibert, None 1435, BE.

Link for CYAD official website?

Official Website of CYAD is: https://www.celyad.com

How do I contact CYAD?

CYAD could be contacted at phone #32 1 039 41 00 and can also be accessed through its website. CYAD operates from Axis Business Park, Mont-Saint-Guibert, None 1435, BE.

How many shares of CYAD are traded daily?

The average number of CYAD shares traded daily for last 3 months was 18.58K.

What is the market cap of CYAD currently?

The market value of CYAD currently stands at $14.24M with its latest stock price at $0.47